Adrenocortical carcinoma.

Area of Science:

• Endocrinology
• Oncology
• Surgical Oncology

Background:

• Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy.
• Early diagnosis is critical for improving patient outcomes and achieving cure.
• Current treatment options for advanced or metastatic ACC are limited, with poor prognoses.

Purpose of the Study:

• To review the current therapeutic landscape for adrenocortical carcinoma.
• To highlight the importance of early diagnosis and surgical intervention.
• To discuss the challenges and future directions in managing ACC, including the need for novel therapeutic agents.

Main Methods:

• Review of existing literature and clinical experiences regarding adrenocortical carcinoma diagnosis and treatment.
• Analysis of the efficacy and toxicity of current therapeutic modalities, including surgical resection and pharmacotherapy (e.g., mitotane).
• Exploration of the role of hormone production in ACC symptomatology and treatment strategies.

Main Results:

• Surgical resection remains the most promising curative treatment for adrenocortical carcinoma.
• Treatment for extensive local or metastatic disease is often discouraging, with limited survival benefits.
• Mitotane, while effective, frequently presents unacceptable toxicity, limiting its use.

Conclusions:

• Prompt diagnosis and surgical management are paramount for adrenocortical carcinoma cure.
• The development of novel, less toxic chemotherapeutic agents and hormonal blockade strategies is essential to improve patient comfort and survival in advanced ACC.
• Further research is needed to address the challenges in treating this rare malignancy, requiring collaboration between oncologists and endocrinologists.